ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

Phentermine Hydrochloride

HCID 70969
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1197-21-3
標準SMILES
CC(C)(N)Cc1ccccc1.Cl
InChIKey
NCAIGTHBQTXTLR-UHFFFAOYSA-N
分子式
C10H16ClN
平均分子量
185.69 g/mol
単同位体質量
185.0971272

概要

Phentermine Hydrochloride is the hydrochloride salt form of phentermine, a sympathomimetic amine with central nervous system (CNS) stimulant and appetite depressant properties. Phentermine hydrochloride stimulates the release of norepinephrine and dopamine from nerve endings and blocks the reuptake of these monoamines at the neuronal junctions, resulting in CNS stimulation and metabolic effects, including appetite-suppression, decreased gastric acid secretion and increased blood pressure.

名称と識別子

優先名称
Phentermine Hydrochloride
IUPAC
2-methyl-1-phenylpropan-2-amine;hydrochloride

名称と別名

Phentermine hydrochloride1197-21-3Phentermine HClFastinOby-TrimToraOna-MastObestin-30SuprenzaWilpoZantrylLomaira
名称をさらに表示
Phenyl-t-butylamine hydrochloridePhentermine hydrochloride civNSC-440901-Phenyl-2-methyl-2-aminopropane hydrochloride0K2I505OTVPhentermine hydrochloride [USP]Benzeneethanamine, alpha,alpha-dimethyl, hydrochloridePhentermine hydrochloride (USP)

データベース識別子

CAS
1197-21-3
PubChem CID
70969
DTXSID
DTXSID20152550
ChEMBL
CHEMBL1200912
UNII
0K2I505OTV
EC Number
214-821-9

物性

構造計算による物性

極性表面積
26 Ų
水素結合供与体数
2
水素結合受容体数
1
回転可能結合数
2
重原子数
12
形式電荷
0
複雑度
112

実験および物理化学的性質

Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Anti-Obesity Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 79 reports by companies from 1 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory InformationBenzeneethanamine, .alpha.,.alpha.-dimethyl-, hydrochloride: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - Benzeneethanamine, .alpha.,.alpha.-dimethyl-, hydrochloride: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (100%)

毒性情報

Treatment · 1 件

Management of acute phentermine intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (REGITINE) has been suggested for possible acute, severe hypertension, if this complicates phentermine overdosage. (L1712)

Health Effects · 1 件

Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion.

化学と産業

薬理情報

Metabolism/MetabolitesHepatic. Half Life: 16 to 31 hours
FDA Pharmacological Classification · 4 件

PHENTERMINE HCL C-IV

Increased Sympathetic Activity [PE]; Appetite Suppression [PE]; Sympathomimetic Amine Anorectic [EPC]

PHENTERMINE HYDROCHLORIDE

Appetite Suppression [PE]; Sympathomimetic Amine Anorectic [EPC]; Increased Sympathetic Activity [PE]

MeSH Pharmacological Classification · 4 件

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Agents that are used to suppress appetite.

Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

用途と製造

UsesFor the treatment and management of obesity.

関連反応

9 件
反応記録を作成
HRID 329908 の反応式
HRID 329908反応物として
HRID 1437130 の反応式
HRID 1437130反応物として
HRID 1484012 の反応式
HRID 1484012反応物として
HRID 1484013 の反応式
HRID 1484013反応物として
HRID 1484014 の反応式
HRID 1484014反応物として
HRID 1484015 の反応式
HRID 1484015反応物として
HRID 1484016 の反応式
HRID 1484016反応物として
HRID 1670799 の反応式
HRID 1670799反応物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Exposure RoutesPhentermine is rapidly absorbed after oral ingestion.
Toxicity Summary · 1 件

Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse.Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.

Signs and SymptomsSymptoms of overdose include delirium, mania, self-injury, marked hypertension, tachycardia, arrhythmia, hyperpyrexia, convulsion, coma, and circulatory collapse.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 15 to 20 mg/kg (monkey).